Page last updated: 2024-11-13

vasoactive intestinal peptide, 4-chloro-phe(6)-leu(17)-

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-: VIP receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID56841988
MeSH IDM0139537

Synonyms (8)

Synonym
(4-cl-d-phe(6),leu(17))vip
vip, 4-cl-phe(6)-leu(17)-
6-(4-chlorophenylalanyl)-17-leucine-vip
vasoactive intestinal peptide, 4-chlorophenylalanyl(6)-leucine(17)-
vasoactive intestinal peptide, 4-chloro-phe(6)-leu(17)-
6-(4-chloro-phe)-17-leu-vasoactive intestinal peptide
juv62c7gcr ,
unii-juv62c7gcr

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The behavior as antagonists of both [4-Cl-D-Phe6,Leu17]VIP and [Ac-Tyr1,D-Phe2]GRF1-29-NH2 was confirmed by: (a) the parallel shifts of the VIP dose-response curves for stimulation of adenylate cyclase activity in the presence of the antagonists; (b) the close agreement between the binding affinity and the inhibition of adenylate cyclase activity for the two peptides; and (c) the lack of effect of the two antagonists upon the adenylate cyclase activity stimulated by the beta-adrenoceptor agonist isoproterenol which indicates the specificity of the interaction."( Vasoactive intestinal peptide receptor antagonists in rat seminal vesicle membranes.
Guijarro, LG; Prieto, JC; Rodríguez-Pena, MS, 1991
)
0.28
" Two consecutive dose-response curves at 20 min apart were determined in the control group."( Evidence for vasoactive intestinal peptide as a mediator of non-adrenergic non-cholinergic neurotransmission in the trachea.
Holmes, EP; O'Malley, NA; Venugopalan, CS, 1990
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (50)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (18.00)18.7374
1990's32 (64.00)18.2507
2000's8 (16.00)29.6817
2010's1 (2.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.61 (24.57)
Research Supply Index3.99 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other53 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]